| Ytd | 0.93% | |
| 1y | 5.35% |
| Open | 14.20 | Prev Close | 14.11 | Low | 14.15 | High | 14.29 | Mkt Cap | 11.80B |
| Vol | 1.79M | Avg Vol | 2.93M | EPS | 0.36 | P/E | 39.36 | Forward P/E | 21.39 |
| Beta | 0.25 | Short Ratio | 8.16 | Inst. Own | 14.93% | Dividend | 0.08 | Div Yield | 0.59 |
| Ex Div Date | 07-09 | Earning | 01-21 | 50-d Avg | 12.50 | 200-d Avg | 13.21 | 1yr Est | 14.31 |
RDY News
Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results des
Semaglutide supply reloading will begin by November 2026. Base business revenue grew double digits e
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript
Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $90
Dr Reddy’s Laboratories (NYSE:RDY) reported second-quarter financial results on Friday. The transcri
Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.12 per share which missed t
American Express headlines Friday’s reports, with premium-card spending and consumer resilience the
Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. In
Dr. Reddy's Laboratories Ltd (NYSE: RDY - Get Free Report)'s share price crossed above its 200-day m
Citigroup analyst Vivek Agrawal upgrades Dr Reddy's Laboratories (NYSE:RDY) from Sell to Buy
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
Dr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company f
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
Dr Reddy's Laboratories (NYSE:RDY) held its first-quarter earnings conference call on Wednesday.
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laborato
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, to
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder righ
Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy's Laboratories (â
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf
Dr. Reddy's (RDY) stock drops after missing Q1 FY27 earnings & revenue estimates. Semaglutid
Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.06 per share which missed t
Companies Reporting Before The Bell • Northern Trust (NASDAQ:NTRS) is expected to report quarterly e
Dr Reddy's Laboratories (NYSE:RDY) released fourth-quarter financial results and hosted an earni
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that
The launch follows Dr. Reddy's receipt of the Notice of Compliance (NOC) from Health Canada on A
Dr. Reddy's launched generic Semaglutide Injection in Canada, expanding its GLP-1 portfolio and
Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.03 per share which missed t
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with
https://www.bloomberg.com/news/articles/2026-04-28/canada-approves-its-first-generic-version-of-novo
https://www.sec.gov/Archives/edgar/data/1135951/000157587226000247/rdy0885_6k.htm
India's drugmakers roll out low-cost copies for Novo Nordisk's semaglutide, slashing prices
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with
https://www.reuters.com/business/healthcare-pharmaceuticals/dr-reddys-aims-launch-generic-obesity-dr
Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage b
Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.16 per share which met the
https://www.bloomberg.com/news/articles/2026-01-21/dr-reddy-s-to-start-selling-generic-ozempic-in-in
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate ov
On Monday, 524 stocks hit new 52-week lows.
On Friday, 368 stocks hit new 52-week lows.